87 results on '"Oliver Cornely"'
Search Results
2. Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol
- Author
-
Clemens Warnke, Stephanie Stock, Martin Hellmich, Gereon R Fink, Heidrun Golla, Raymond Voltz, Judith Haas, Julia Strupp, Volker Limmroth, Anne Müller, Eckhard Bonmann, Kim Dillen, Thomas Dojan, Solveig Ungeheuer, Petra Schmalz, Angelika Staß, Vanessa Mildenberger, Yasemin Goereci, Veronika Dunkl, Oliver Cornely, Alexander Stahmann, Peter Löcherbach, Lothar Burghaus, Kathrin Gerbershagen, Gereon Nelles, Thomas Joist, and Herbert Temmes
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
3. Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis
- Author
-
Stefanie Wunsch, Christoph Zurl, Heimo Strohmaier, Andreas Meinitzer, Jasmin Rabensteiner, Wilfried Posch, Cornelia Lass-Flörl, Oliver Cornely, Gudrun Pregartner, Elisabeth König, Gebhard Feierl, Martin Hoenigl, Juergen Prattes, Ines Zollner-Schwetz, Thomas Valentin, and Robert Krause
- Subjects
interleukin 17A ,interleukins ,cytokines ,biomarker ,Candida ,invasive candidiasis ,Biology (General) ,QH301-705.5 - Abstract
Interleukin (IL) 17A plays a decisive role in anti-Candida host defense. Previous data demonstrated significantly increased IL-17A values in candidemic patients. We evaluated levels and time courses of IL-17A, and other cytokines suggested to be involved in Candida-specific immunity (IL-6, IL-8, IL-10, IL-17F, IL-22, IL-23, interferon-γ, tumor necrosis factor-α, Pentraxin-related protein 3, transforming growth factor-β) in patients with invasive candidiasis (IC) compared to bacteremic patients (Staphylococcus aureus, Escherichia coli) and healthy controls (from previous 4 days up to day 14 relative to the index culture (−4; 14)). IL-17A levels were significantly elevated in all groups compared to healthy controls. In IC, the highest IL-17A values were measured around the date of index sampling (−1; 2), compared to significantly lower levels prior and after sampling the index culture. Candidemic patients showed significantly higher IL-17A values compared to IC other than candidemia at time interval (−1; 2) and (3; 7). No significant differences in IL-17A levels could be observed for IC compared to bacteremic patients. Candidemic patients had higher IL-8, IL-10, IL-22, IFN-γ, PTX3 and TNF-α values compared to non-candidemic. Based on the limited discriminating competence between candidemia and bacteremia, IL-17A has to be considered a biomarker for blood stream infection rather than invasive Candida infection.
- Published
- 2021
- Full Text
- View/download PDF
4. Catheterless long-term ambulatory urodynamic measurement using a novel three-device system.
- Author
-
Sebastian Wille, Pauline Schumacher, Jenny Paas, Dirk Tenholte, Okyaz Eminaga, Ute Müller, Noemi Muthen, Jan Mehner, Oliver Cornely, and Udo Engelmann
- Subjects
Medicine ,Science - Abstract
AimsLong-term urodynamics are required because bladder-emptying disorders are often not clearly revealed by conventional urodynamics. Patients with severe clinical overactive bladder symptoms, for instance, often show normal results. This may be due to the short evaluation time and psychological factors that complicate conventional urodynamics. This study aimed to develop an ambulatory three-component urodynamic measurement system that is easy to operate, registers urodynamic parameters for several days, and has no negative impact on the patient.MethodsWe developed an intravesical capsule combined with a hand-held device to register voiding desire and micturition, and an alarm pad device that detects urine loss. Recently, the intravesical capsule and its proven function were detailed in the literature. Here, we present detailed in vitro results using a female bladder model. The flexible capsule was C-shaped to minimize the risk of expulsion from the bladder during micturition. Results of biocompatibility evaluation of the intravesical capsule, which is called Wille Capsule (WiCa) are described.ResultsThe WiCa with an oval nose and a maximum outer diameter of 5.5 mm was easily inserted through a 25-French cystoscope. Removing the WiCa by grasping the nose using the female model with bladder was easily conducted. Expulsion of the WiCa during voiding was avoided through a novel C-shaped device design. Based on in vitro cytotoxicity studies, the capsule is a promising and safe device.ConclusionOur novel system is an innovative minimally-invasive tool for accurate long-term urodynamic measurement, and does not require inserting a transurethral catheter.
- Published
- 2014
- Full Text
- View/download PDF
5. Severe Pneumonia and Human Bocavirus in Adult
- Author
-
Bernd Kupfer, Jörg Vehreschild, Oliver Cornely, Rolf Kaiser, Gerhard Plum, Sergei Viazov, Caspar Franzen, Ramona-Liza Tillmann, Arne Simon, Andreas Müller, and Oliver Schildgen
- Subjects
bocavirus ,respiratory ,cancer ,high-risk patients ,letter ,Germany ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Published
- 2006
- Full Text
- View/download PDF
6. COVID-19–associated mucormycosis: a systematic review and meta-analysis of 958 cases
- Author
-
Laşin Özbek, Umur Topçu, Mehtap Manay, Buğra Han Esen, Sevval Nur Bektas, Serhat Aydın, Barış Özdemir, Sofya N. Khostelidi, Nikolai Klimko, Oliver Cornely, Johnny Zakhour, Souha S. Kanj, Danila Seidel, Martin Hoenigl, and Önder Ergönül
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Published
- 2023
7. SARS-CoV-2 vaccination in CLL: how often is enough?
- Author
-
Oliver Cornely and Sibylle Mellinghoff
- Subjects
COVID-19 Vaccines ,SARS-CoV-2 ,Seroconversion ,Vaccination ,Immunology ,Immunity ,Humans ,COVID-19 ,Cell Biology ,Hematology ,Leukemia, Lymphocytic, Chronic, B-Cell ,Biochemistry - Published
- 2022
8. Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis
- Author
-
Sarah Heringer, Oliver Cornely, Jan Grothe, and Rosanne Sprute
- Subjects
Pharmacology ,Microbiology (medical) ,Infectious Diseases ,Antifungal Agents ,Humans ,Pharmacology (medical) ,Candidiasis, Invasive - Abstract
Objectives Enrolment of subjects to clinical trials investigating novel drugs for infectious diseases is an ongoing challenge. In this study, we evaluate factors associated with non-enrolment in treatment trials for invasive candidiasis. Methods We conducted a retrospective review of pre-screening logs of patients that were assessed for enrolment in the three clinical trials ACTIVE (NCT00413218), APX001-201 (NCT03604705) and ReSTORE (NCT03667690), investigating novel drugs for invasive candidiasis between September 2007 and August 2021 to identify reasons for study ineligibility. Results Two hundred and fifty-six patients with invasive candidiasis were identified for potential study participation with n = 154 for the ACTIVE trial, n = 89 for APX001-201 and n = 13 for ReSTORE. Half of the potential participants were unable or unwilling to consent. We further identified comorbid conditions such as hepatic or renal impairment [21 hepatic and renal cases (13.6%) in ACTIVE; 12 hepatic (13.5%) and 28 renal cases (31.5%) in APX], prior antifungal treatment [11 cases (7.1%) in ACTIVE; 16 (18.0%) in APX; 7 (38.5%) in ReSTORE] and the last positive culture obtained ≥96 h prior to dosing [1 case (0.6%) in ACTIVE; 7 (7.9%) in APX; 5 (38.5%) in ReSTORE] as relevant reasons for non-enrolment. We also identified criteria repetitively used in the analysed studies that did not contribute substantially to ineligibility rates. Ultimately, 254/256 patients (99.2%) were ineligible for enrolment in the respective trial. Conclusions This study identified barriers to enrolment in clinical trials assessing novel antifungal agents in invasive candidiasis. Identification of eligibility criteria associated with non-enrolment allows modification of future trial designs and may ultimately result in higher recruitment rates.
- Published
- 2022
9. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
- Author
-
Francesco Marchesi, Jon Salmanton-Garcia, Ziad EMARAH, Klára PIUKOVICS, Marcio Nucci, Alberto Lopez-Garcia, Zdenek Racil, Francesca Farina, Marina POPOVA, Sofia ZOMPI, Ernesta Audisio, Marie-Pierre Ledoux, Luisa VERGA, Barbora Weinbergerova, Tomas Szotkowski, Maria Silva, Nicola Stefano Fracchiolla, Nick DE JONGE, Graham Collins, Monia Marchetti, Gabriele MAGLIANO, Carolina GARCÍA-VIDAL, Monika M. BIERNAT, Jaap van Doesum, Marina MACHADO, Fatih Demirkan, Murtadha Al Khabori, Pavel Zak, Benjamin Visek, Igor STOMA, Gustavo-Adolfo MÉNDEZ, Johan Maertens, Nina KHANNA, Ildefonso Espigado, Giulia DRAGONETTI, Luana Fianchi, Maria Ilaria Del Principe, Alba CABIRTA, Irati ORMAZABAL-VÉLEZ, Ozren Jaksic, Caterina BUQUICCHIO, Valentina BONUOMO, Josip Batinić, Ali S. OMRANI, Sylvain Lamure, Olimpia Finizio, Noemí FERNÁNDEZ, Iker FALCES-ROMERO, Ola BLENNOW, Rui BERGANTIM, Natasha Ali, Sein WIN, Jens VAN PRAET, Maria Chiara Tisi, Ayten SHIRINOVA, Martin SCHÖNLEIN, Juergen PRATTES, Monica PIEDIMONTE, Verena Petzer, Milan NAVRÁTIL, Austin Kulasekararaj, Pavel Jindra, null Jiří, Andreas Glenthøj, Rita FAZZI, Cristina de Ramón, Chiara Cattaneo, Maria CALBACHO, Nathan C. BAHR, Shaimaa Saber EL-ASHWL, Raúl Córdoba, Michaela HANAKOVA, Giovanni ZAMBROTTA, Mariarita Sciumè, Stephen Booth, Raquel NUNES-RODRIGUES, Maria Vittoria SACCHI, Nicole GARCÍA-POUTÓN, Juan-Alberto MARTÍN-GONZÁLEZ, Sofya KHOSTELIDI, Stefanie GRÄFE, Laman RAHIMLI, alessandro busca, Paolo Corradini, Martin HOENIGL, Nikolai KLIMKO, Philipp Koehler, Antonio PAGLIUCA, Francesco Passamonti, Oliver Cornely, and Livio pagano
- Subjects
hemic and lymphatic diseases ,neoplasms - Abstract
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died. Death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%). Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed. Patients with COVID-19 diagnosis between January and August 2020 had a significantly lower survival. COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment.
- Published
- 2022
10. Update on the 'Choosing Wisely' initiative in infectious diseases in Germany
- Author
-
Marylyn Addo, Frank Hanses, Jan Rupp, Oliver Cornely, and Stefan Hagel
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Review ,030204 cardiovascular system & hematology ,Communicable Diseases ,03 medical and health sciences ,Patient safety ,0302 clinical medicine ,Germany ,Health care ,medicine ,Humans ,Meningitis ,In patient ,030212 general & internal medicine ,Intensive care medicine ,Societies, Medical ,Venipuncture ,medicine.diagnostic_test ,Lumbar puncture ,business.industry ,Vaccination ,General Medicine ,medicine.disease ,Choosing Wisely ,Infectious Diseases ,Blood cultures ,Practice Guidelines as Topic ,business ,Delivery of Health Care ,Blood drawing - Abstract
Purpose The Choosing Wisely® initiative is an international campaign addressing over- and underuse of diagnostic and therapeutic measures in infectious diseases among others. Since 2016, the German Society for Infectious Diseases (DGI) has constantly designed new items in this regard. Here we report the most recent recommendations. Methods The recommendations of the DGI are part of the “Klug entscheiden” initiative of the German Society of Internal Medicine (DGIM). Topics for the new items were suggested by members of the DGI, checked for scientific evidence and consented within the DGI and the DGIM before publication. Results The new recommendations are: (1) individuals with immune-suppression, advanced liver cirrhosis or renal insufficiency should receive a dual pneumococcal vaccination. (2) In case of positive blood cultures with Candida spp. thorough diagnostics and treatment should be initiated. (3) In case of suspected meningitis, adult patients should receive dexamethasone and antibiotics immediately after venipuncture for blood cultures and before potential imaging. (4) In case of suspected meningitis a CT scan before lumbar puncture should not be ordered—except for symptoms indicating high CSF pressure or focal brain pathology or in cases of severe immune-suppression. (5) In patients with suspected severe infections, a minimum of two pairs of blood cultures should be drawn using separate venipunctures prior to antibiotic therapy—regardless of body temperature. There is no need of a minimum time interval in between the blood draws. Conclusion Applying these new Choosing Wisely® recommendations will increase patient safety and the value of health care.
- Published
- 2020
11. OUP accepted manuscript
- Author
-
Jean-Pierre Gangneux, Oliver Cornely, and Elena Daniela Serban
- Subjects
Infectious Diseases ,General Medicine - Published
- 2022
12. Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol
- Author
-
Heidrun Golla, Kim Dillen, Martin Hellmich, Thomas Dojan, Solveig Ungeheuer, Petra Schmalz, Angelika Staß, Vanessa Mildenberger, Yasemin Goereci, Veronika Dunkl, Julia Strupp, Gereon R Fink, Raymond Voltz, Stephanie Stock, Oliver Cornely, Alexander Stahmann, Anne Müller, Peter Löcherbach, Lothar Burghaus, Volker Limmroth, Eckhard Bonmann, Kathrin Gerbershagen, Gereon Nelles, Thomas Joist, Judith Haas, Herbert Temmes, and Clemens Warnke
- Subjects
Cocos ,Multiple Sclerosis ,Communication ,Palliative Care ,General Medicine ,adult palliative care ,quality in health care ,Clinical Trials, Phase II as Topic ,Caregivers ,ddc: 610 ,Medicine and health ,Quality of Life ,Humans ,Medicine ,ddc:610 ,Randomized Controlled Trials as Topic - Abstract
IntroductionPatients with multiple sclerosis (MS) have complex needs that range from organising one’s everyday life to measures of disease-specific therapy monitoring to palliative care. Patients with MS are likely to depend on multiple healthcare providers and various authorities, which are often difficult to coordinate. Thus, they will probably benefit from comprehensive cross-sectoral coordination of services provided by care and case management (CCM). Though studies have shown that case management improves quality of life (QoL), functional status and reduces service use, such benefits have not yet been investigated in severely affected patients with MS. In this explorative phase ll clinical trial, we evaluated a CCM with long-term, cross-sectoral and outreaching services and, in addition, considered the unit of care (patients and caregivers).Methods and analysisEighty patients with MS and their caregivers will be randomly assigned to either the control (standard care) or the intervention group (standard care plus CCM (for 12 months)). Regular data assessments will be done at baseline and then at 3-month intervals. As primary outcome, we will evaluate patients’ QoL. Secondary outcomes are patients’ treatment-related risk perception, palliative care needs, anxiety/depression, use of healthcare services, caregivers’ burden and QoL, meeting patients’ and caregivers’ needs, and evaluating the CCM intervention. We will also evaluate CCM through individual interviews and focus groups. The sample size calculation is based on a standardised effect of 0.5, and one baseline and four follow-up assessments (with correlation 0.5). Linear mixed models for repeated measures will be applied to analyse changes in quantitative outcomes over time. Multiple imputation approaches are taken to assess the robustness of the results. The explorative approach (phase ll clinical trial) with embedded qualitative research will allow for the development of a final design for a confirmative phase lll trial.Ethics and disseminationThe trial will be conducted under the Declaration of Helsinki and has been approved by the Ethics Commission of Cologne University’s Faculty of Medicine. Trial results will be published in an open-access scientific journal and presented at conferences.Trial registration numberGerman Register for Clinical Studies (DRKS) (DRKS00022771).
- Published
- 2022
13. Impact of Guideline adherence on outcome in Candidemia : Results from the ECMM Candida III multinational European study
- Author
-
Egger, M., Honigl, M., Salmanton--Garcia, J., Arendrup, M. C., Kohler, P., Gangneux, J. P., Bicanic, T., Arikan--Akdagli, S., Lass-Florl, C., Prattes, J., Willinger, B., Steinmann, J., Seufert, R., Trauth, J., Scharmann, U., Khanna, N., Adam, K. M., Meijer, E., and Oliver Cornely
- Subjects
Medizin - Abstract
Objectives: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe in order to assess how adherence to guideline recommendations correlate with outcome Methods: Each participating hospital included the first ~10 culture proven IC cases after 01-Jul-18 and entered data into the ECMM Candida III database on the FungiScope™ platform. EQUAL Candida Scores reflecting adherence to Guideline recommendations were assessed. Results: A total of 632 Candidemia cases were included from 64 institutions in 20 European countries. Overall mortality was 45% (286/632), and hospital stay was prolonged (median 2 days), for completion of parenteral therapy only, in 16% (100/621) of patients. EQUAL Candida Score was evaluable for 589 cases with candidemia. Candida scores correlated significantly with duration of hospitalization (r = 0.442; p
- Published
- 2022
14. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
- Author
-
Carina Saggau, Gabriela Rios Martini, Elisa Rosati, Silja Meise, Berith Messner, Ann-Kristin Kamps, Nicole Bekel, Johannes Gigla, Ruben Rose, Mathias Voß, Ulf M. Geisen, Hayley M. Reid, Melike Sümbül, Florian Tran, Dennis K. Berner, Yascha Khodamoradi, Maria J.G.T. Vehreschild, Oliver Cornely, Philipp Koehler, Andi Krumbholz, Helmut Fickenscher, Oliver Kreuzer, Claudia Schreiber, Andre Franke, Stefan Schreiber, Bimba Hoyer, Alexander Scheffold, and Petra Bacher
- Subjects
Infectious Diseases ,SARS-CoV-2 ,Immunoglobulin G ,Vaccination ,Immunology ,Immunity ,Receptors, Antigen, T-Cell ,COVID-19 ,Humans ,Immunology and Allergy ,Antibodies, Viral ,Aged - Abstract
SARS-CoV-2 infection and vaccination generates enormous host-response heterogeneity and an age-dependent loss of immune-response quality. How the pre-exposure T cell repertoire contributes to this heterogeneity is poorly understood. We combined analysis of SARS-CoV-2-specific CD4
- Published
- 2022
15. Comment on: Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching
- Author
-
Oliver Cornely, Jan Grothe, and Rosanne Sprute
- Subjects
Pharmacology ,Microbiology (medical) ,Infectious Diseases ,Pharmacology (medical) - Published
- 2022
16. Harmonized procedure coding system for surgical procedures of five European countries (Preprint)
- Author
-
Sibylle Mellinghoff, Carolin Bruns, Rouvier Al-Monajjed, Florian Cornely, Maria Grosheva, Juergen Hampl, Carolin Jakob, Felix Koehler, Max Lechmann, Bijan Maged, Christina Otto-Lambertz, Robert Rongisch, Jule Rutz, Jon Salmanton-Garcia, Georg Schlachtenberger, Jannik Stemler, Janne Vehreschild, Sophia Wuelfing, Oliver Cornely, and Blasius Liss
- Abstract
BACKGROUND Surgical site infections (SSI) are frequent hospital acquired complications. Ongoing surveillance pro-grams evaluate the incidence of SSI worldwide. However, incidence rates are only estimated by the analyses of indicator procedures to date. OBJECTIVE To further assess procedure specific SSI rates, the harmonization of international procedure codes is necessary. METHODS We compared existing surgical procedure coding systems of five European countries (France, Ger-many, Italy, Spain, and the UK) and distributed a simplified code to all existing country-specific codes. Based on mode and extent of the surgical procedure and the surgical site, 153 codes were defined, distributed, and characterized within the presented coding system. Additionally, minimally invasive, laparoscopic or open surgical approaches were considered, whereas eye surgery and di-agnostic procedures were excluded. RESULTS A total number of 15432 surgical procedures were assigned to 153 SALT codes from 10 specialties. Almost 4000 (26%) procedure codes from the SALT coding system were classified as orthopaedic and trauma surgeries, thus this medical field represents the most diverse group within the SALT coding system, followed by abdominal surgical procedures with 2390 (15%) procedure codes. CONCLUSIONS The Europe-wide SALT procedure code gives the opportunity to harmonize big data sets containing surgical procedures from international centres, and may simplify comparability of future interna-tional trial findings.
- Published
- 2021
17. Session
- Author
-
Oliver Cornely and Laszlo Irinyi
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2019
18. Postersession
- Author
-
Oliver Cornely
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2019
19. 123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
- Author
-
Peter G Pappas, Oliver Cornely, Philipp Koehler, Todd P McCarty, Barbara D Alexander, Rachel Miller, Jose A Vazquez, John W Sanders, Caryn Morse, Luis Ostrosky-Zeichner, Robert Krause, Jürgen Prattes, Andrej Spec, Riina Rautemaa-Richardson, Rohit Bazaz, Thomas J Walsh, Francisco M Marty, Isabel H Gonzalez-Bocco, Marisa Miceli, Martin Hoenigl, Thomas F Patterson, Nkechi Azie, and David A Angulo
- Subjects
Infectious Diseases ,AcademicSubjects/MED00290 ,Oncology ,Oral Abstracts ,education ,health care economics and organizations - Abstract
Background Candida species are a major cause of invasive and mucocutaneouls infections. There are limited oral treatment options available for patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals. Oral ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients intolerant of or with fungal disease refractory to standard antifungal therapy. We present an analysis of patient outcomes from the FURI study by fungal disease type. Table 1: FURI Outcomes by Fungal Disease Methods FURI patients were eligible for enrollment if they have proven or probable, severe mucocutaneous candidiasis, invasive candidiasis or invasive aspergillosis,other fungal diseases and evidence of failure to, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or can not receive approved oral antifungal options (e.g., susceptibility of the organism) and a continued IV antifungal therapy is clinically undesirable or unfeasible. Results An independent Data Review Committee (DRC) provided an assessment of treatment response for 74 patients enrolled in the FURI study from 22 centers in US, UK and EU treated with ibrexafungerp for mucocutaneous or invasive fungal infections from 2016- 2020. A total of 39 (52.7%) patients had invasive candidiasis, 32 (43.2%) had mucocutaneous candidiasis and 3 (4.5%) patients had invasive aspergillosis. The percent of patients who were determined to have a complete response (CR), partial response (PR), clinical improvement (CI) was 63.5%, stable disease (SD) was 23.0%, patients with progression of disease 6.8% and 4 patients were indeterminate. Additionally, there was 1 death in the FURI study that was not related to fungal disease. Table 1 shows outcomes by fungal disease type as determined by the DRC. Conclusion Analysis of 74 patients from the FURI study indicates that oral ibrexafungerp provides a favorable therapeutic response in patients with challenging fungal disease and limited treatment options. Disclosures Peter G. Pappas, MD, Astellas (Research Grant or Support)Cidara (Research Grant or Support)F2G (Consultant)Matinas (Consultant, Scientific Research Study Investigator)Mayne Pharma (Research Grant or Support)Scynexis (Research Grant or Support) Oliver Cornely, Prof., Actelion (Consultant, Grant/Research Support)Al-Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Consultant)Amplyx (Consultant, Grant/Research Support)Astellas (Consultant, Grant/Research Support)Basilea (Consultant, Grant/Research Support)Biocon (Consultant)Biosys (Consultant)Cidara (Consultant, Grant/Research Support)CoRe Consulting (Consultant)Da Volterra (Consultant, Grant/Research Support)DFG (German Research Foundation) (Grant/Research Support)Entasis (Consultant)F2G (Consultant, Grant/Research Support)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Grant/Research Support)Grupo Biotoscana (Consultant)Immunic (Grant/Research Support)IQVIA (Consultant)Janssen (Grant/Research Support)Matinas (Consultant)Medicines Company (Grant/Research Support)MedPace (Consultant, Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini (Consultant)Merck/MSD (Consultant, Grant/Research Support)Molecular Partners (Consultant)MSG-ERC (Consultant)Mylan (Consultant)Nabriva (Consultant)Noxxon (Consultant)Octapharma (Consultant)Paratek (Consultant)Pfizer (Consultant, Grant/Research Support)PSI (Consultant)Roche Diagnostics (Consultant)Scynexis (Consultant, Grant/Research Support)Seres (Consultant)Shionogi (Consultant)Wiley (Blackwell) (Other Financial or Material Support) Philipp Koehler, MD, Ambu GmbH (Consultant, Speaker's Bureau)Astellas Pharma (Speaker's Bureau)Euopean Confederation of Medical Mycology (Speaker's Bureau)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Speaker's Bureau)MSD (Speaker's Bureau)Noxxon N.V. (Consultant)Pfizer (Speaker's Bureau)State of North Rhine-Westphalia, Germany (Grant/Research Support) Todd P. McCarty, MD, Cidara (Grant/Research Support)GenMark (Grant/Research Support, Other Financial or Material Support, Honoraria for Research Presentation)T2 Biosystems (Consultant) Barbara D. Alexander, MD, MHS, SCYNEXIS, Inc. (Consultant) Rachel Miller, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Caryn Morse, MD, Chimerix (Scientific Research Study Investigator)Covis Pharma (Scientific Research Study Investigator)Gilead Sciences Inc. (Scientific Research Study Investigator)Ridgeback Biotherapeutics (Scientific Research Study Investigator)Roche (Scientific Research Study Investigator)SCYNEXIS, Inc. (Scientific Research Study Investigator)Theratechnologies (Advisor or Review Panel member)Viiv (Advisor or Review Panel member) Luis Ostrosky-Zeichner, MD, Amplyx (Consultant)Cidara (Consultant)F2G (Consultant)Gilead (Grant/Research Support, Speaker's Bureau)Pfizer (Scientific Research Study Investigator, Speaker's Bureau)Scynexis (Grant/Research Support, Scientific Research Study Investigator)Viracor (Consultant) Jürgen Prattes, Dr, AbbVie Inc. (Shareholder)Gilead (Speaker's Bureau)MSD (Grant/Research Support)Novo Nordisk (Shareholder)Pfizer (Advisor or Review Panel member)Stryker (Shareholder) Andrej Spec, MD, MSCI, Mayne Pharma (Grant/Research Support) Riina Rautemaa-Richardson, DDS, PhD, FRCPath, SCYNEXIS, Inc. (Scientific Research Study Investigator) Thomas J. Walsh, MD, PhD (hon), Scynexis (Consultant, Grant/Research Support)Shionogi (Consultant, Grant/Research Support) Francisco M. Marty, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Marisa Miceli, MD, SCYNEXIS, Inc. (Advisor or Review Panel member) Martin Hoenigl, MD, Astellas (Grant/Research Support)Gilead (Grant/Research Support)Pfizer (Grant/Research Support) Martin Hoenigl, MD, Astellas (Individual(s) Involved: Self): Grant/Research Support; F2G (Individual(s) Involved: Self): Grant/Research Support; Gilead (Individual(s) Involved: Self): Grant/Research Support; Pfiyer (Individual(s) Involved: Self): Grant/Research Support; Scýnexis (Individual(s) Involved: Self): Grant/Research Support Thomas F. Patterson, MD, SCYNEXIS, Inc. (Advisor or Review Panel member) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2021
20. 992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)
- Author
-
Jose A Vazquez, Oliver Cornely, Philipp Koehler, Riina Rautemaa-Richardson, Rohit Bazaz, G Marshall Lyon, Francisco M Marty, Isabel H Gonzalez-Bocco, Rachel Miller, Thomas J Walsh, Peter Pappas, Todd P McCarty, John W Sanders, Caryn Morse, Luis Ostrosky-Zeichner, Robert Krause, Jürgen Prattes, Andrej Spec, David Andes, Oliver Witzke, Nkechi Azie, and David A Angulo
- Subjects
Infectious Diseases ,Oncology ,education - Abstract
Background Candida albicans is the predominant organism causing esophageal candidiasis (EC) and oropharyngel candidiasis (OPC). These infections may arise from subjects colonized with Candida who are predisposed due to illness, debility or a local reduction in host resistance to an overgrowth of their own indigenous flora. Patients with mucocutaneous Candida infections can be treated in the outpatient setting, yet there are limited oral treatment options available for patients who are unresponsive to or who are intolerant to currently available antifungals. Oral ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients intolerant of or with fungal disease refractory to standard antifungal therapy. Table 1. FURI Outcomes in OPC and EC Methods FURI subjects were eligible for enrollment if they had proven or probable severe mucocutaneous candidiasis, invasive candidiasis, invasive aspergillosis, or other fungal diseases with evidence of treatment failure, intolerance, or toxicity related to a currently approved standard-of-care antifungal treatment or if they were unable to receive an approved oral antifungal option (e.g., susceptibility of the organism) and a continued IV antifungal therapy was clinically undesirable or unfeasible. Results An independent Data Review Committee (DRC) provided an assessment of treatment response for 74 subjects enrolled in the FURI study from 22 centers in US, UK and EU treated with ibrexafungerp for mucocutaneous or invasive fungal infections from 2016- 2020. A total 32 subjects (43.2%) had mucocutaneous candidiasis and 24 subjects were diagnosed with OPC or EC. The percent of patients who were determined to have a complete response (CR) or partial response (PR) was 62.5%, stable disease (SD), 20.8%, and progression of disease, 16.7%. Table 1 shows outcomes by EC and OPC as determined by the DRC. Conclusion Analysis of 24 EC and OPC patients from the FURI study indicates that oral ibrexafungerp provides a favorable therapeutic response in patients with challenging mucocutaneous fungal disease and limited treatment options. Disclosures Oliver Cornely, Prof., Actelion (Consultant, Grant/Research Support)Al-Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Consultant)Amplyx (Consultant, Grant/Research Support)Astellas (Consultant, Grant/Research Support)Basilea (Consultant, Grant/Research Support)Biocon (Consultant)Biosys (Consultant)Cidara (Consultant, Grant/Research Support)CoRe Consulting (Consultant)Da Volterra (Consultant, Grant/Research Support)DFG (German Research Foundation) (Grant/Research Support)Entasis (Consultant)F2G (Consultant, Grant/Research Support)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Grant/Research Support)Grupo Biotoscana (Consultant)Immunic (Grant/Research Support)IQVIA (Consultant)Janssen (Grant/Research Support)Matinas (Consultant)Medicines Company (Grant/Research Support)MedPace (Consultant, Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini (Consultant)Merck/MSD (Consultant, Grant/Research Support)Molecular Partners (Consultant)MSG-ERC (Consultant)Mylan (Consultant)Nabriva (Consultant)Noxxon (Consultant)Octapharma (Consultant)Paratek (Consultant)Pfizer (Consultant, Grant/Research Support)PSI (Consultant)Roche Diagnostics (Consultant)Scynexis (Consultant, Grant/Research Support)Seres (Consultant)Shionogi (Consultant)Wiley (Blackwell) (Other Financial or Material Support) Philipp Koehler, MD, Ambu GmbH (Consultant, Speaker’s Bureau)Astellas Pharma (Speaker’s Bureau)Euopean Confederation of Medical Mycology (Speaker’s Bureau)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Speaker’s Bureau)MSD (Speaker’s Bureau)Noxxon N.V. (Consultant)Pfizer (Speaker’s Bureau)State of North Rhine-Westphalia, Germany (Grant/Research Support) Riina Rautemaa-Richardson, DDS, PhD, FRCPath, SCYNEXIS, Inc. (Scientific Research Study Investigator) G. Marshall Lyon, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Francisco M. Marty, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Rachel Miller, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Thomas J. Walsh, MD, PhD (hon), Scynexis (Consultant, Grant/Research Support)Shionogi (Consultant, Grant/Research Support) Peter Pappas, MD, Astellas (Grant/Research Support)Cidara (Grant/Research Support, Advisor or Review Panel member)Mayne (Grant/Research Support, Advisor or Review Panel member)Merck (Grant/Research Support)SCYNEXIS, Inc. (Consultant, Grant/Research Support) Todd P. McCarty, MD, Cidara (Grant/Research Support)GenMark (Grant/Research Support, Other Financial or Material Support, Honoraria for Research Presentation)T2 Biosystems (Consultant) Caryn Morse, MD, Chimerix (Scientific Research Study Investigator)Covis Pharma (Scientific Research Study Investigator)Gilead Sciences Inc. (Scientific Research Study Investigator)Ridgeback Biotherapeutics (Scientific Research Study Investigator)Roche (Scientific Research Study Investigator)SCYNEXIS, Inc. (Scientific Research Study Investigator)Theratechnologies (Advisor or Review Panel member)Viiv (Advisor or Review Panel member) Luis Ostrosky-Zeichner, MD, Amplyx (Consultant)Cidara (Consultant)F2G (Consultant)Gilead (Grant/Research Support, Speaker’s Bureau)Pfizer (Scientific Research Study Investigator, Speaker’s Bureau)Scynexis (Grant/Research Support, Scientific Research Study Investigator)Viracor (Consultant) Jürgen Prattes, Dr, AbbVie Inc. (Shareholder)Gilead (Speaker’s Bureau)MSD (Grant/Research Support)Novo Nordisk (Shareholder)Pfizer (Advisor or Review Panel member)Stryker (Shareholder) Andrej Spec, MD, MSCI, SCYNEXIS, Inc. (Consultant, Scientific Research Study Investigator) David Andes, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Oliver Witzke, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2021
21. Performance of existing definitions and tests for the diagnosis of invasive fungal diseases other than invasive candidiasis and invasive aspergillosis in critically ill, adult patients : a systematic review with qualitative evidence synthesis
- Author
-
Cornelia Lass-Flörl, Daniele Roberto Giacobbe, Valentina Zuccaro, Erika Asperges, Chiara Rebuffi, Luigia Scudeller, Toine Mercier, Stijn Blot, Ilias Karaiskos, Dylan De Lange, Frederic Lamoth, Maddalena Peghin, Oliver Cornely, Sofia Tejada, Ana Alastruey-Izquierdo, Giacobbe, Daniele R, Cortegiani, Andrea, Karaiskos, Ilia, Mercier, Toine, Tejada, Sofia, Peghin, Maddalena, Grecchi, Cecilia, Rebuffi, Chiara, Asperges, Erika, Zuccaro, Valentina, Scudeller, Luigia, Bassetti, Matteo, The Fundicu Investigators, null, Institut Català de la Salut, [Giacobbe DR] Department of Health Sciences, University of Genoa, 16132 Genoa, Italy. Clinica Malattie Infettive, Ospedale Policlinico San Martino–IRCCS, 16132 Genoa, Italy. [Cortegiani A] Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, 90127 Palermo, Italy. Department of Anaesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, 90127 Palermo, Italy. [Karaiskos I] Hygeia General Hospital, 15123 Athens, Greece. [Mercier T] Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium. Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium. [Tejada S] Grup d’Investigació Clínica/Epidemiologia en Pneumònia i Sèpsia (CRIPS), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28220 Madrid, Spain. [Peghin M] Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, 33100 Udine, Italy, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
diagnosis ,infecciones bacterianas y micosis::micosis::infecciones fúngicas invasoras [ENFERMEDADES] ,invasive fungal diseases ,PJP ,Plant Science ,Aspergillosis ,Bacterial Infections and Mycoses::Mycoses::Invasive Fungal Infections [DISEASES] ,law.invention ,0302 clinical medicine ,IFD ,biomarker ,pneumocystis ,law ,Diagnosis ,Other subheadings::/diagnosis [Other subheadings] ,Medicine and Health Sciences ,030212 general & internal medicine ,lcsh:QH301-705.5 ,0303 health sciences ,Natural Science Disciplines::Science::Research::Empirical Research::Qualitative Research [DISCIPLINES AND OCCUPATIONS] ,Ecology ,Communication ,Pneumocystis jirovecii Pneumonia ,Invasive candidiasis ,Intensive care unit ,Invasive fungal diseases ,Systematic review ,Microbiology (medical) ,medicine.medical_specialty ,Evolution ,Qualitative evidence ,Otros calificadores::/diagnóstico [Otros calificadores] ,Investigació qualitativa ,03 medical and health sciences ,Behavior and Systematics ,disciplinas de las ciencias naturales::ciencia::investigación::investigación empírica::investigación cualitativa [DISCIPLINAS Y OCUPACIONES] ,medicine ,Intensive care medicine ,Ecology, Evolution, Behavior and Systematics ,Adult patients ,030306 microbiology ,Critically ill ,business.industry ,Pneumocystis ,Biomarker ,medicine.disease ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,lcsh:Biology (General) ,Micosi - Diagnòstic ,business - Abstract
Diagnòstic; Malalties fúngiques invasores; Pneumocystis Diagnóstico; Enfermedades fúngicas invasivas; Pneumocystis Diagnosis; Invasive fungal diseases; Pneumocystis The Fungal Infections Definitions in Intensive Care Unit (ICU) patients (FUNDICU) project aims to provide standard sets of definitions for invasive fungal diseases (IFDs) in critically ill, adult patients, including invasive aspergillosis (IA), invasive candidiasis (IC), Pneumocystis jirovecii pneumonia (PJP), and other non-IA, non-IC IFDs. The first step of the project was the conduction of separated systematic reviews of the characteristics and applicability to critically ill, adult patients outside classical populations at risk (hematology patients, solid organ transplant recipients) of available definitions and diagnostic tests for IFDs. We report here the results of two systematic reviews exploring the performance of available definitions and tests, for PJP and for other non-IA, non-IC IFDs. Starting from 2585 and 4584 records for PJP and other IFDs, respectively, 89 and 61 studies were deemed as eligible for full-text evaluation. However, only two studies for PJP and no studies for other IFDs met the FUNDICU protocol criteria for inclusion in qualitative synthesis. Currently, there is no sufficient solid data for directly evaluating the performance of existing definitions and laboratory tests for the diagnosis of PJP and other non-IA, non-IC IFDs in critically ill adult patients outside classical populations at risk. The present project did not require additional funding from routine research activities. Costs for open-access publications were covered by research funds of the main authors.
- Published
- 2021
22. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases
- Author
-
Marie, von Lilienfeld-Toal, Jörg Janne, Vehreschild, Oliver, Cornely, Livio, Pagano, Francesca, Compagno, and Zdenek, Racil
- Subjects
Quality of life ,Infection Control ,Infectious Disease Transmission, Patient-to-Professional ,SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Betacoronavirus ,Myeloproliferative disease ,Neoplasms ,Practice Guidelines as Topic ,Correspondence ,Humans ,Patient Care ,Coronavirus Infections ,Pandemics - Abstract
Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
- Published
- 2020
23. 983. Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)
- Author
-
John W Sanders, Caryn Morse, Oliver Cornely, Philipp Koehler, Robert Krause, Jürgen Prattes, Guenter Weiss, Nkechi Azie, and David A Angulo
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Candida osteoarticular infections are often preceded by candidemia with the intervertebral discs and knee joints the most common area for candidemic seeding. Candida osteomyelitis has significant morbidity and diagnosis is often delayed difficult to treat. Treatment courses are usually long and there are limited oral options available for patients who have an azole-resistant infection. Oral ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients with fungal disease refractory or who intolerant of to standard of care antifungal therapy. Table 1. FURI Bone and Joint Infection Outcomes Methods FURI subjects were eligible for enrollment if they have proven or probable, severe mucocutaneous candidiasis, invasive candidiasis or invasive aspergillosis and documented evidence of failure to, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or can not receive approved oral antifungal options (e.g., susceptibility of the organism) or a continued IV antifungal therapy is clinically undesirable or unfeasible. Results An independent Data Review Committee (DRC) provided an assessment of treatment response for a total 74 subjects enrolled in the FURI study from 22 centers in US, UK and EU treated with ibrexafungerp for mucocutaneous or invasive fungal infections from 2016- 2020. There were 8 subjects out of the 74 subjects who were diagnosed with various bone and joint infections, 5 subjects with spondylodiscitis, 1 subject with a knee/prosthetic joint infection and 2 subjects with bone infections, one of the tibia and one of the zygomatic arch. Table 1 shows outcomes for this patient group, five (75%) patients had a clinical benefit (complete or partial response and stable response), one (12.5%) had progression of disease and one patient was indeterminate. The median days of therapy for this group was 210.5 days. Conclusion Analysis of 8 subjects from the FURI study indicates that oral ibrexafungerp provides a promising therapeutic response in option for patients with bone and/or joint infections. Disclosures Caryn Morse, MD, Chimerix (Scientific Research Study Investigator)Covis Pharma (Scientific Research Study Investigator)Gilead Sciences Inc. (Scientific Research Study Investigator)Ridgeback Biotherapeutics (Scientific Research Study Investigator)Roche (Scientific Research Study Investigator)SCYNEXIS, Inc. (Scientific Research Study Investigator)Theratechnologies (Advisor or Review Panel member)Viiv (Advisor or Review Panel member) Oliver Cornely, Prof., Actelion (Consultant, Grant/Research Support)Al-Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Consultant)Amplyx (Consultant, Grant/Research Support)Astellas (Consultant, Grant/Research Support)Basilea (Consultant, Grant/Research Support)Biocon (Consultant)Biosys (Consultant)Cidara (Consultant, Grant/Research Support)CoRe Consulting (Consultant)Da Volterra (Consultant, Grant/Research Support)DFG (German Research Foundation) (Grant/Research Support)Entasis (Consultant)F2G (Consultant, Grant/Research Support)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Grant/Research Support)Grupo Biotoscana (Consultant)Immunic (Grant/Research Support)IQVIA (Consultant)Janssen (Grant/Research Support)Matinas (Consultant)Medicines Company (Grant/Research Support)MedPace (Consultant, Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini (Consultant)Merck/MSD (Consultant, Grant/Research Support)Molecular Partners (Consultant)MSG-ERC (Consultant)Mylan (Consultant)Nabriva (Consultant)Noxxon (Consultant)Octapharma (Consultant)Paratek (Consultant)Pfizer (Consultant, Grant/Research Support)PSI (Consultant)Roche Diagnostics (Consultant)Scynexis (Consultant, Grant/Research Support)Seres (Consultant)Shionogi (Consultant)Wiley (Blackwell) (Other Financial or Material Support) Philipp Koehler, MD, Ambu GmbH (Consultant, Speaker’s Bureau)Astellas Pharma (Speaker’s Bureau)Euopean Confederation of Medical Mycology (Speaker’s Bureau)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Speaker’s Bureau)MSD (Speaker’s Bureau)Noxxon N.V. (Consultant)Pfizer (Speaker’s Bureau)State of North Rhine-Westphalia, Germany (Grant/Research Support) Jürgen Prattes, Dr, AbbVie Inc. (Shareholder)Gilead (Speaker’s Bureau)MSD (Grant/Research Support)Novo Nordisk (Shareholder)Pfizer (Advisor or Review Panel member)Stryker (Shareholder) Guenter Weiss, MD, MSD (Speaker’s Bureau)Novartis (Speaker’s Bureau)Pfizer (Speaker’s Bureau)Pharmacosmos (Speaker’s Bureau)Scynexis (Scientific Research Study Investigator)Vifor (Speaker’s Bureau) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2021
24. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology
- Author
-
Cornelia Lass-Flörl, SILVIA CAMPOS, Glen Westall, PAOLO GROSSI, Letizia Corinna Morlacchi, AMPARO SOLE, Prof. Jens Gottlieb, Jérôme Le Pavec, M. Teresa Martin Gomez, Victor Monforte, Johanna Claustre, Carlos Cervera, Julien Coussement, Hossein Zarrinfar, Nikolaus Kneidinger, Dima Kabbani, Lorenzo Rosso, Effrossyni Gkrania-Klotsas, José Manuel Cifrián, Mathieu Puyade, Blandine Rammaert, Andrea Dell'Amore, Oliver Cornely, Saima Aslam, Shahid Husain, Oriol Manuel, and Lieven Dupont
- Subjects
Response rate (survey) ,Transplantation ,medicine.medical_specialty ,Respiratory tract infections ,business.industry ,medicine.medical_treatment ,030230 surgery ,3. Good health ,Scedosporium ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Internal medicine ,medicine ,Lung transplantation ,030211 gastroenterology & hepatology ,Colonization ,Prospective cohort study ,business ,Contraindication - Abstract
BACKGROUND Scedosporium species and Lomentospora prolificans (S/L) are the second most common causes of invasive mold infections following Aspergillus in lung transplant recipients. METHODS We assessed the current practices on management of S/L colonization/infection of the lower respiratory tract before and after lung transplantation in a large number of lung transplant centers through an international practice survey from October 2016 to March 2017. RESULTS A total of 51 respondents from 45 lung transplant centers (17 countries, 4 continents) answered the survey (response rate 58%). S/L colonization was estimated to be detected in candidates by 48% of centers. Only 18% of the centers used a specific medium to detect S/L colonization. Scedosporium spp. colonization was a contraindication to transplantation in 10% of centers whereas L prolificans was a contraindication in 31%; 22% of centers declared having had 1-5 recipients infected with S/L in the past 5 years. CONCLUSIONS This survey gives an overview of the current practices regarding S/L colonization and infection in lung transplant centers worldwide and underscores the need of S/L culture procedure standardization before implementing prospective studies.
- Published
- 2019
25. Antifungal susceptibility profiles of rare ascomycetous yeasts
- Author
-
Cornelia Lass-Flörl, Maurizio Sanguinetti, Petr Hamal, Karsten Becker, Arnaldo Lopes Colombo, Sarah Kidd, and Oliver Cornely
- Subjects
Pharmacology ,Microbiology (medical) ,Candida inconspicua ,Antiinfective agent ,Pichia norvegensis ,Antifungal Agents ,Broth microdilution ,Microbial Sensitivity Tests ,Candida pararugosa ,Biology ,Sensitivity and Specificity ,Microbiology ,Candida rugosa ,Infectious Diseases ,Ascomycota ,Mycoses ,Humans ,Trichomonascus ciferrii ,Pharmacology (medical) ,Etest - Abstract
ObjectivesTo generate antifungal susceptibility patterns for Trichomonascus ciferrii (Candida ciferrii), Candida inconspicua (Torulopsis inconspicua) and Diutina rugosa species complex (Candida rugosa species complex), and to provide key parameters such as MIC50, MIC90 and tentative epidemiological cut-off values (TECOFFs).MethodsOur strain set included isolates of clinical origin: C. inconspicua (n = 168), D. rugosa species complex (n = 90) [Candida pararugosa (n = 60), D. rugosa (n = 26) and Candida mesorugosa (n = 4)], Pichia norvegensis (Candida norvegensis) (n = 15) and T. ciferrii (n = 8). Identification was performed by MALDI-TOF MS or internal transcribed spacer sequencing. Antifungal susceptibility patterns were generated for azoles, echinocandins and amphotericin B using commercial Etest and the EUCAST broth microdilution method v7.3.1. Essential agreement (EA) was calculated for Etest and EUCAST.ResultsC. inconspicua, C. pararugosa and P. norvegensis showed elevated azole MICs (MIC50 ≥0.06 mg/L), and D. rugosa and C. pararugosa elevated echinocandin MICs (MIC50 ≥0.06 mg/L). EA between methods was generally low (ConclusionsRare yeast species tested shared high fluconazole MICs. D. rugosa species complex displayed high echinocandin MICs, while C. inconspicua and P. norvegensis were found to have high azole MICs. Overall, the agreement between EUCAST and Etest was poor and therefore MIC values generated with Etest cannot be directly compared with EUCAST results.
- Published
- 2019
26. 1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
- Author
-
Barbara D Alexander, Oliver Cornely, Peter Pappas, Rachel Miller, Jose A Vazquez, Luis Ostrosky-Zeichner, Andrej Spec, Riina Rautemaa-Richardson, Robert Krause, George R Thompson III, Caryn Morse, John W Sanders, David Andes, George Lyon, Francisco M Marty, Emily Silverman, Marisa H Miceli, Thomas F Patterson, Martin Hoenigl, Nkechi Azie, and David A Angulo
- Subjects
medicine.medical_specialty ,business.industry ,Candida esophagitis ,Disease progression ,Pathogenicity ,Interim analysis ,AcademicSubjects/MED00290 ,Infectious Diseases ,New england ,Oncology ,Open label study ,Refractory ,Internal medicine ,Poster Abstracts ,medicine ,Adverse effect ,business - Abstract
Background Candida infections resistant to currently available antifungals are an emerging global threat. Ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of oral ibrexafungerp (FURI) (Clinicaltrials.gov NCT03059992) is ongoing for the treatment of patients (≥18 years) with fungal diseases who are intolerant of or refractory to standard antifungal therapies. Methods An independent Data Review Committee (DRC) provided an assessment of treatment response for 41 patients. Patients were enrolled in 22 centers from 6 countries. Patients were eligible for enrollment if they had proven or probable, invasive or severe mucocutaneous candidiasis and documented evidence of failure of, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or could not receive approved oral antifungal options (e.g., susceptibility of the organism) and a continued IV antifungal therapy was undesirable or unfeasible. Results The 41 patients assessed had the following infection types: intra-abdominal abscesses, oropharyngeal candidiasis, esophageal candidiasis, candidemia, and others. The DRC adjudicated 23 patients (56%) as achieving complete or partial response, 11 patients (27%) maintaining stable disease, 6 patients (15%) with progression of disease and one case was considered as indeterminate. The efficacy of oral ibrexafungerp by pathogen is shown in Table 1. Ibrexafungerp was well-tolerated with the most common treatment-related adverse events being of gastrointestinal origin. No deaths due to progression of fungal disease were reported. Table 1: Ibrexafungerp Outcomes by Pathogen Conclusion Preliminary analysis of these 41 cases indicate that oral ibrexafungerp provides a favorable therapeutic response in the majority of patients with difficult to treat Candida spp. infections, including those caused by non-albicans Candida species. Disclosures Barbara D. Alexander, MD, MHS, SCYNEXIS, Inc. (Employee, Scientific Research Study Investigator, Research Grant or Support) Oliver Cornely, Prof., Actelion (Grant/Research Support)Actelion (Other Financial or Material Support, Personal fees)Al Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Other Financial or Material Support, Personal fees)Amplyx (Other Financial or Material Support, Personal fees)Amplyx (Grant/Research Support)Astellas (Grant/Research Support)Astellas (Other Financial or Material Support, Personal fees)Basilea (Other Financial or Material Support, Personal fees)Basilea (Grant/Research Support)Biosys UK Limited (Other Financial or Material Support, Personal fees)Cidara (Other Financial or Material Support, Personal fees)Cidara (Grant/Research Support)Da Volterra (Grant/Research Support)Da Volterra (Other Financial or Material Support, Personal fees)Entasis (Other Financial or Material Support, Personal fees)F2G (Other Financial or Material Support)F2G (Grant/Research Support)Gilead (Grant/Research Support)Gilead (Other Financial or Material Support, Personal fees)Grupo Biotoscana (Other Financial or Material Support, Personal fees)Janssen Pharmaceuticals (Grant/Research Support)Matinas (Other Financial or Material Support, Personal fees)Medicines Company (Grant/Research Support)MedPace (Grant/Research Support)MedPace (Other Financial or Material Support, Personal fees)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche (Other Financial or Material Support, Personal fees)Merck/MSD (Other Financial or Material Support, Personal fees)Merck/MSD (Grant/Research Support)Mylan Pharmaceuticals (Consultant)Nabriva Therapeutics (Other Financial or Material Support, Personal fees)Octapharma (Other Financial or Material Support, Personal fees)Paratek Pharmaceuticals (Other Financial or Material Support, Personal fees)Pfizer (Other Financial or Material Support, Personal fees)Pfizer (Grant/Research Support)PSI (Other Financial or Material Support, Personal fees)Rempex (Other Financial or Material Support, Personal fees)Roche Diagnostics (Other Financial or Material Support, Personal fees)Scynexis (Other Financial or Material Support, Personal fees)Scynexis (Grant/Research Support)Seres Therapeutics (Other Financial or Material Support, Personal fees)Tetraphase (Other Financial or Material Support, Personal fees) Peter Pappas, MD, SCYNEXIS, Inc. (Consultant, Advisor or Review Panel member, Research Grant or Support) Rachel Miller, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Luis Ostrosky-Zeichner, MD, Amplyx (Scientific Research Study Investigator)Astellas (Consultant, Scientific Research Study Investigator, Other Financial or Material Support, Non-branded educational speaking)Biotoscana (Consultant, Other Financial or Material Support, Non-branded educational speaking)Cidara (Consultant, Scientific Research Study Investigator)F2G (Consultant)Gilead (Consultant)Mayne (Consultant)Octapharma (Consultant)Pfizer (Other Financial or Material Support, Non-branded educational speaking)Scynexis (Consultant, Grant/Research Support, Scientific Research Study Investigator)Stendhal (Consultant)Viracor (Consultant) Andrej Spec, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator, Advisor or Review Panel member) Riina Rautemaa-Richardson, DDS, PhD, FRCPath, SCYNEXIS, Inc. (Scientific Research Study Investigator) Robert Krause, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Caryn Morse, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) John W. Sanders, III, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) David Andes, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator, Advisor or Review Panel member) George Lyon, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Francisco M. Marty, MD, Allovir (Consultant)Amplyx (Consultant)Ansun (Scientific Research Study Investigator)Avir (Consultant)Cidara (Scientific Research Study Investigator)F2G (Consultant, Scientific Research Study Investigator)Kyorin (Consultant)Merck (Consultant, Grant/Research Support, Scientific Research Study Investigator)New England Journal of Medicine (Other Financial or Material Support, Honorarium for Video)Regeneron (Consultant, Scientific Research Study Investigator)ReViral (Consultant)Scynexis (Scientific Research Study Investigator)Symbio (Consultant)Takeda (Scientific Research Study Investigator)United Medical (Consultant)WHISCON (Scientific Research Study Investigator) Marisa H. Miceli, MD, FIDSA, SCYNEXIS, Inc. (Advisor or Review Panel member) Thomas F. Patterson, MD, SCYNEXIS, Inc. (Advisor or Review Panel member) Martin Hoenigl, MD, SCYNEXIS, Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2020
27. Candida-reactive T cells for the diagnosis of invasive Candida infection
- Author
-
Alexander Scheffold and Oliver Cornely
- Published
- 2018
28. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines
- Author
-
Malgorzata Mikulska, Diana Averbuch, Frederic Tissot, Catherine Cordonnier, Murat Akova, Thierry Calandra, Marcello Ceppi, Paolo Bruzzi, Claudio Viscoli, Mahmoud Aljurf, Dina Averbuch, Rosemary Barnes, Ola Blennow, Pierre-Yves Bochud, Emilio Bouza, Stephane Bretagne, Roger Brüggemann, Jordi Carratala, Simone Cesaro, Oliver Cornely, Tina Dalianis, Rafael De La Camara, Peter Donnelly, Lubos Drgona, Rafael Duarte, Hermann Einsele, Dan Engelhard, Christopher Fox, Corrado Girmenia, Andreas Groll, Dag Heldal, Jannick Helweg Larsen, Raoul Herbrecht, Hans Hirsch, Elisabeth Johnson, Galina Klyasova, Minna Koskuenvo, Katrien Lagrou, Russel E. Lewis, Per Ljungman, Johan Maertens, Georg Maschmeyer, Marcio Nucci, Christophe Padoin, Livio Pagano, Antonio Pagliuca, Zdenek Racil, Patricia Ribaud, Christine Rinaldo, Valérie Rizzi Puechal, Emmanuel Roilides, Christine Robin, Montserrat Rovira, Markus Rupp, Sonia Sanchez, Peter Schellongowski, Peter Sedlacek, Janos Sinko, Monica Slavin, Isabella Sousa Ferreira, Jan Styczynski, Katherine Ward, Anne-Therese Witschi, Mikulska, Malgorzata, Averbuch, Diana, Tissot, Frederic, Cordonnier, Catherine, Akova, Murat, Calandra, Thierry, Ceppi, Marcello, Bruzzi, Paolo, Viscoli, Claudio, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yve, Bouza, Emilio, Bretagne, Stephane, Brüggemann, Roger, Carratala, Jordi, Cesaro, Simone, Cornely, Oliver, Dalianis, Tina, De La Camara, Rafael, Donnelly, Peter, Drgona, Lubo, Duarte, Rafael, Einsele, Hermann, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andrea, Heldal, Dag, Larsen, Jannick Helweg, Herbrecht, Raoul, Hirsch, Han, Johnson, Elisabeth, Klyasova, Galina, Koskuenvo, Minna, Lagrou, Katrien, Lewis, Russel E., Ljungman, Per, Maertens, Johan, Maschmeyer, Georg, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rinaldo, Christine, Puechal, Valérie Rizzi, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Marku, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Jano, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Ward, Katherine, and Witschi, Anne-Therese
- Subjects
Neutropenic ,Microbiology (medical) ,Ciprofloxacin ,Febrile neutropenia ,Infection ,Levofloxacin ,Multidrug resistance (MDR) ,Prevention ,Quinolone ,medicine.medical_specialty ,Neutropenia ,Guidelines as Topic ,Infections ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Ciprofloxacin, Febrile neutropenia, Infection, Levofloxacin, Multidrug resistance (MDR), Neutropenic, Prevention, Quinolone, Microbiology (medical), Infectious Diseases ,030212 general & internal medicine ,Intensive care medicine ,Infection Control ,business.industry ,Antibiotic Prophylaxis ,medicine.disease ,Anti-Bacterial Agents ,Settore MED/15 - MALATTIE DEL SANGUE ,Resistant bacteria ,Critical appraisal ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Infectious Diseases ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Haematological cancer ,Observational study ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Fluoroquinolones - Abstract
Contains fulltext : 190513.pdf (Publisher’s version ) (Closed access) OBJECTIVES: Fluoroquinolone (FQ) prophylaxis was recommended in 2005 by European Conference on Infections in Leukemia (ECIL) for patients with prolonged neutropenia. In consideration of a worldwide increase in antibiotic resistance, the issue of FQ prophylaxis during neutropenia was re-evaluated. METHODS: Literature review of randomised controlled trials (RCT) and observational studies published in years 2006-2014 was performed. Their results were analysed in meta-analysis. Meta-regression model was applied to evaluate whether the rates of FQ resistance in community and hospital settings influenced the efficacy of FQ prophylaxis. The impact of FQ prophylaxis on colonisation and infection with resistant bacteria was reviewed. RESULTS: Two RCTs and 12 observational studies were identified. FQ prophylaxis did not have effect on mortality (pooled OR 1.01, 95%CI 0.73-1.41), but was associated with lower rate of bloodstream infections (BSI) (pooled OR 0.57, 95%CI 0.43-0.74) and episodes of fever during neutropenia (pooled OR 0.32, 95%CI 0.20-0.50). No effect of the background rate of FQ resistance on the efficacy of FQ prophylaxis was observed. In few studies, FQ prophylaxis resulted in an increased colonisation or infection with FQ- or multi-drug resistant strains. CONCLUSIONS: The possible benefits of FQ prophylaxis on BSI rate, but not on overall mortality, should be weighed against its impact in terms of toxicity and changes in local ecology in single centres.
- Published
- 2018
29. Pneumonie unter Immunsuppression: Antimikrobielle Substanzen
- Author
-
Santiago Ewig and Oliver Cornely
- Published
- 2017
30. Erreger
- Author
-
Santiago Ewig, Oliver Cornely, and Sören Gatermann
- Published
- 2017
31. Antimikrobielle Substanzen
- Author
-
Santiago Ewig and Oliver Cornely
- Published
- 2017
32. Epidemiology of Surgical Site Infections With Staphylococcus aureus in Europe: Protocol for a Retrospective, Multicenter Study (Preprint)
- Author
-
Jörg Janne Vehreschild, Blasius Janusch Liss, Oliver Cornely, and Sibylle Mellinghoff
- Abstract
BACKGROUND Surgical site infections (SSIs) are among the most common hospital acquired infections. While the incidence of SSI in certain indicator procedures is the subject of ongoing surveillance efforts in hospitals and health care systems around the world, SSI rates vary markedly within surgical categories and are poorly represented by routinely monitored indicator procedures (eg, mastectomy or hernia surgery). Therefore, relying on indicator procedures to estimate the burden of SSI is imprecise and introduces bias as hospitals may take special precautions to achieve lower SSI rates. The most common cause of SSI is Staphylococcus aureus (S. aureus), as recently confirmed by a Europe-wide point-prevalence study conducted by the European Centre for Disease Prevention and Control (ECDC). OBJECTIVE The primary objective of this study is to determine the overall and procedure-specific incidence of S. aureus SSI in Europe. Secondary objectives are the overall and procedure-specific outcomes as well as the economic burden of S. aureus SSI in Europe. Explorative objectives are to characterize the composition of the surgical patient population and to estimate the number of patients at risk for S. aureus SSI. METHODS A retrospective, multinational, multicenter cohort study (Staphylococcus aureus Surgical Site Infection Multinational Epidemiology in Europe [SALT] study) with a nested case-control part will be conducted. The study will include all surgical procedures at a participating center in order to prevent selection bias and strengthen the understanding of SSI risk by determining the incidence for all common surgical procedures. Data will be assessed in the cohort population, including 150,000 adult patients who underwent any surgical procedure in 2016, and the case-control population. We will match patients establishing S. aureus SSI 1:1 with controls from the same center. Data on demographics, surgery, and microbiology will be exported from electronic files. More detailed data will be captured from the case-control population. The SALT study will include 13 major or academic surgical centers in Europe, comprising 3 in France, 4 in Germany, 2 in Italy, 3 in Spain, and 1 in the United Kingdom. Sites were selected using a feasibility questionnaire. RESULTS The SALT study is currently recruiting patients. The aim is to complete recruitment in February 2018 and to close the database in September 2018. The final results are expected by the end of 2018. CONCLUSIONS Results of the SALT study will help to better understand the precise risk of certain procedures. They will also provide insight into the overall and procedure-specific incidence and outcome as well as the economic burden of S. aureus SSI in Europe. Findings of the study may help guide the design of clinical trials for S. aureus vaccines. CLINICALTRIAL ClinicalTrials.gov NCT03353532; https://clinicaltrials.gov/ct2/show/NCT03353532 (Archived by WebCite at http://www.webcitation.org/6xAK3gVmO)
- Published
- 2017
33. Pneumonie unter Neutropenie
- Author
-
Santiago Ewig and Oliver Cornely
- Published
- 2017
34. Correction
- Author
-
Oliver Cornely
- Subjects
General Medicine ,Applied Microbiology and Biotechnology ,Microbiology - Published
- 2019
35. 43rd Annual Meeting of the German-Speaking Mycological Society (DMykG)
- Author
-
Oliver Cornely
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2009
36. Fungal endocarditis
- Author
-
Oliver Cornely and Yoav Keynan
- Subjects
Infectious Diseases - Published
- 2007
37. PTX3 Deficiency and Aspergillosis
- Author
-
Jörg Janne Vehreschild, Agostinho Carvalho, Cristina Cunha, Oliver Kurzai, and Oliver Cornely
- Subjects
Male ,business.industry ,Neutrophils ,medicine.medical_treatment ,MEDLINE ,Hematopoietic Stem Cell Transplantation ,General Medicine ,PTX3 ,Hematopoietic stem cell transplantation ,Aspergillosis ,medicine.disease ,Polymorphism, Single Nucleotide ,Immunity, Innate ,Serum Amyloid P-Component ,Text mining ,C-Reactive Protein ,Immunity ,Polymorphism (computer science) ,Immunology ,medicine ,Humans ,Female ,business - Published
- 2014
38. Mucormycosis
- Author
-
Oliver Cornely
- Published
- 2011
39. Idiotype vaccination for Non-Hodgkin lymphoma
- Author
-
Vera Ossendorf, Oliver Cornely, Andreas Draube, Ina Monsef, Andreas Engert, and Nicole Skoetz
- Published
- 2011
40. Infektiologie
- Author
-
Matthias Kochanek, Guido Michels, Gerd Fätkenheuer, Oliver Cornely, Ute Aurbach, Harald Seifert, Christian Gutschow, Dirk Waldschmidt, Jan Rybniker, Emmanouil Skouras, Maria J.G.T. Vehreschild, and Janne Vehreschild
- Published
- 2011
41. Onkologie
- Author
-
Matthias Kochanek, Oliver Cornely, and Guido Michels
- Published
- 2011
42. Onkologie
- Author
-
Matthias Kochanek, Oliver Cornely, and Guido Michels
- Published
- 2010
43. Infektiologie
- Author
-
Matthias Kochanek, Guido Michels, Susann Koch, Gerd Fätkenheuer, Oliver Cornely, Ute Aurbach, Harald Seifert, Christian Gutschow, Dirk Waldschmitt, Gero von Gersdorff, Jan Rybniker, Emmanouil Skouras, Maria Rüping, and Janne Vehreschild
- Published
- 2010
44. Adressenverzeichnis
- Author
-
Michael Böhm, Michael Hallek, Wolff Schmiegel, Guido Adler, Ali-Asa Alexander Aghdassi, Hans-Dieter Allescher, Bruno Allolio, Peter Angerer, C.E. Angermann, Christina Bähr, Daniel C. Baumgart, Claudia Bausewein, F. Ulrich Beil, Dirk Beuckelmann, Felix Beuschlein, Eberhard Blind, Christoph Bode, Ulrich Bogdahn, Christian Bojarski, Carsten Bokemeyer, Peter Bottermann, Thorsten Brechmann, Gerd-Rüdiger Burmester, Meinhard Classen, Oliver Cornely, Paula Cramer, Bodo Cremers, Volker Diehl, Annette Dieing, Markus Dietlein, Hartmut Döhner, Manfred O. Doss, A. Dünne, Andreas Engert, Georg Ertl, Gerd Fätkenheuer, Jürgen Floege, Andreas Franke, N. Frickhofen, Th. Gain, Jan Galle, Peter R. Galle, Birgit Gathof, Angela Gause, Guido Gerken, Beate Gleissner, Burkhard Göke, Rüdiger Göke, Ullrich Graeven, A. Greinacher, Friedrich Grimminger, Wolfgang Ludwig Gross, Peter Gross, Frank Grünhage, Andreas Günther, Peter Hanrath, Werner E. Hansen, Pia Hartmann, M. Haupts, Dieter Häussinger, Ekkehart Heidbreder, Michael Heike, Robert Heinrich, Stephan Heller, Bernhard Hellmich, Stefan Heringlake, Andreas Hochhaus, Stephan Hollerbach, Uta C. Hoppe, Walter H. Hörl, Dieter Horstkotte, Frank Isken, Rolf-Dieter Issels, Franz Jakob, Tomas Jelinek, Christoph Jochum, Stephan Kanzler, U. Keilholz, Michael Kindermann, Beate Klimm, Günther Klotz, Stefan Tobias Knop, Kurt Kochsiek, Volker Köllner, Hans-Jochem Kolb, Christian Kollmannsberger, Matthias Kraft, Karl-Anton Kreuzer, Heyo Kroemer, Wolfgang Kruis, Markus Kuczyk, Uwe Kühl, Anja Kwetkat, Frank Lammert, Hauke Lang, Ulrich Laufs, Wolfgang Lepper, Markus Lerch, Andreas Link, Andreas van de Loo, Carmen Loquai, Christoph Maack, Michael Peter Manns, Uta Merle, Christian Mewis, null Mertens, Susanne Milhorst, Martin Moser, Harald Morr, Joachim Mössner, Bruno Neu, Horst Neuhaus, Georg Nickenig, Eberhard Nieschlag, Thurid Nolte, Dennis Nowak, Horst Olschewski, Catrin Palm, Klaus G. Parhofer, R. Paschke, Georg Peters, Andreas Pfeiffer, Johannes Pfeilschifter, Michael Pfreundschuh, Michael Philipper, Gerd Pommer, Kurt Possinger, Christian Pox, Lukas Radbruch, Guliano Ramadori, Frank Reichenberger, Anke Reinacher-Schick, Martin Reincke, Marcel Reiser, Markus Reiser, Dieter Rosskopf, Andrea Rubbert, Bernd Salzberger, Tilman Sauerbruch, Ludwig Schaaf, V. Schächinger, Wolfgang von Scheidt, Sebastian Schellong, W. Schepp, Harald Schicha, Uwe Siegfried Schlegel, Roland Schmid, Heinz-Josef Schmitt, Hans-Joachim Schmoll, Jürgen Schölmerich, Heinz-Peter Schultheiss, Richard Schulz, Heribert Schunkert, Werner Seeger, Harald Seifert, Hanns Martin Seitz (Emeritus), H. Serve, Kai Severin, Dirk Skowasch, Michael Spannagl, Peter Staib, Ulrich Stölzel, Christian Straßburg, W. Stremmel, Norbert Suttorp, Christian von Tirpitz, Joachim Thiery, Christian Trautwein, Klaus-Henning Usadel, Hans-Georg Velcovsky, Ulrich Wahnschaffe, Hans-Dieter Walmrath, Ronald Walshe, Christoph Wanner, Hermann Wasmuth, Joachim Weil, Michael Weiß, Clemens Wendtner, Jochen A. Werner, Bertram Wiedenmann, Jörg Willert, Jürgen Wolf, Andreas Zeiher, Martin Zeitz, Stefan Zeuzem, Walter Zidek, Thomas Zilker, Michael Zitzmann, and Carsten Zwick
- Published
- 2009
45. [Oral candidiasis]
- Author
-
Dieter, Reinel, Andreas, Plettenberg, Claus, Seebacher, Dietrich, Abeck, Jochen, Brasch, Oliver, Cornely, Isaak, Effendy, Gabriele, Ginter-Hanselmayer, Norbert, Haake, Gudrun, Hamm, Uta-Christina, Hipler, Herbert, Hof, Hans Christian, Korting, Peter, Mayser, Markus, Ruhnke, Kurt-Heiner, Schlacke, and Hans-Jürgen, Tietz
- Subjects
Adult ,Microbiological Techniques ,Antifungal Agents ,Evidence-Based Medicine ,Dose-Response Relationship, Drug ,Administration, Topical ,Infant, Newborn ,Administration, Oral ,Infant ,Opportunistic Infections ,Drug Administration Schedule ,Diagnosis, Differential ,Candidiasis, Oral ,Humans ,Child - Published
- 2008
46. Orale Candidose
- Author
-
Dieter Reinel, Andreas Plettenberg, Claus Seebacher, Dietrich Abeck, Jochen Brasch, Oliver Cornely, Isaak Effendy, Gabriele Ginter-Hanselmayer, Norbert Haake, Gudrun Hamm, Uta-Christina Hipler, Herbert Hof, Hans Christian Korting, Peter Mayser, Markus Ruhnke, Kurt-Heiner Schlacke, and Hans-Jürgen Tietz
- Subjects
Dermatology - Published
- 2008
47. Onychomykose
- Author
-
Claus Seebacher, Jochen Brasch, Dietrich Abeck, Oliver Cornely, Isaak Effendy, Gabriele Ginter-Hanselmayer, Norbert Haake, Gudrun Hamm, Uta-Christina Hipler, Herbert Hof, Hans Christian Korting, Peter Mayser, Markus Ruhnke, Kurt-Heiner Schlacke, and Hans-Jörgen Tietz
- Subjects
Dermatology - Published
- 2007
48. Cornely OA et al (Clin Infect Dis 2015; 61:324–31)
- Author
-
Oliver Cornely
- Subjects
Microbiology (medical) ,Infectious Diseases - Published
- 2015
49. Corrigendum
- Author
-
Oliver Cornely and Isaak Effendy
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2015
50. Correction: Combination Antifungal Therapy for Invasive Aspergillosis
- Author
-
Oliver Cornely
- Subjects
Internal Medicine ,General Medicine - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.